WW International, Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights: - Digital Transformation: The app and website are being modernized. The app is being replatformed to remove legacy barriers and become a personalized companion using AI and behavioral insights. The website is being rebuilt for a mobile-first experience. - Growing Medical Business: Scaling WeightWatchers Clinic, GLP-1 Companion Program, and Registered Dietitian Network. Investing in new diversified revenue streams, including telehealth and partnerships with pharmaceutical companies. - Brand Modernization: Executing a comprehensive brand refresh, shifting marketing strategy to value-based storytelling, and moving towards a value-based pricing approach. - Operational Improvements: Focus on efficiency, disciplined execution, and resource management. Implementation of AI-powered voice support and integration of clinical and behavioral operations to improve productivity and member experience.

Segment Performance: In the third quarter of 2025, WeightWatchers had behavioral end-of-period subscribers at 2.9 million, a 20% year-over-year decline. Clinical end-of-period subscribers were 124,000, a 60% year-over-year increase. Revenue totaled $172 million, with clinical revenue growing 35% year-over-year and behavioral revenue declining 16% year-over-year. Monthly subscription revenues per average subscriber (ARPU) was $18.52 in the quarter, up 9% compared to the prior year quarter but down sequentially. Adjusted EBITDA was $43 million with an adjusted EBITDA margin of 24.9%. Adjusted gross margin was 75.1%, and adjusted SG&A was 18% of revenue.

Guidance: WeightWatchers narrowed full-year fiscal 2025 guidance to revenue of $695 million to $700 million and adjusted EBITDA of $145 million to $150 million. Anticipates adjusted EBITDA to decline in Q4 2025 compared to Q3 due to increased marketing. Q3 2025 is expected to be the trough in clinical end-of-period subscribers as the transition from compounded medications is largely complete.

Risks: Challenges include competition from compounded GLP-1 medications, downward pressure on medication prices, and retention challenges in the behavioral segment. The prolonged deep discounting strategy has been a hurdle, and transitioning to value-based pricing takes time.

Q: What about the Menopause program launch?

A: Tara Comonte said the Menopause program is an exciting market entry, targeting existing members and new audiences, leveraging clinical expertise, curated communities, and new technology, with a positive brand moment from the launch with Queen Latifah.

Q: Plans for peak season across product and marketing?

A: Tara Comonte mentioned extensive work on digital rebuild, brand refresh, community offerings, and reentry into the market with focus on medication access and holistic offering, anticipating an uptick in subscribers Q1 from Q4, with the peak being the start of many new initiatives like the new app and brand launch.